Skip to main content
SpringerLink
Log in

Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA)

  • Original Paper
  • Published:
World Journal of Microbiology and Biotechnology Aims and scope Submit manuscript

Abstract

It was found in the present study that combined use of fusidic acid (FA) and berberine chloride (BBR) offered an in vitro synergistic action against 7 of the 30 clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, with a fractional inhibitory concentration (FIC) index ranging from 0.5 to 0.19. This synergistic effect was most pronounced on MRSA 4806, an FA-resistant isolate, with a minimum inhibitory concentration (MIC) value of 1,024 μg/ml. The time-kill curve experiment showed that FA plus BBR yielded a 4.2 log10 c.f.u./ml reduction in the number of MRSA 4806 bacteria after 24-h incubation as compared with BBR alone. Viable count analysis showed that FA plus BBR produced a 3.0 log10 c.f.u./ml decrease in biofilm formation and a 1.5 log10 c.f.u./ml decrease in mature biofilm in viable cell density as compared with BBR alone. In addition, phase contrast micrographs confirmed that biofilm formation was significantly inhibited and mature biofilm was obviously destructed when FA was used in combination with BBR. These results provide evidence that combined use of FA and BBR may prove to be a promising clinical therapeutic strategy against MRSA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Alou L, Cafini F, Sevillano D, Unzueta I, Prieto J (2004) In vitro activity of mupirocin and amoxicillin-clavulanate alone and in combination against staphylococci including those resistant to methicillin. Int J Antimicrob Agents 23(5):513–516

    Article  CAS  Google Scholar 

  • Chaieb K, Kouidhi B, Jrah H, Mahdouani H, Bakhrouf A (2011) Antibacterial activity of Thymoquinone, an active principle of Nigella sativa and its potency to prevent bacterial biofilm formation. BMC Complement Altern Med 11:29

    Article  CAS  Google Scholar 

  • Christiansen K (1999) Fusidic acid adverse drug reactions. Int J Antimicrob Agents 12(Suppl 2):S3–S9

    Article  CAS  Google Scholar 

  • Christoffersen RE (2006) Antibiotics—an investment worth making? Nat Biotechnol 24(12):1512–1514

    Article  CAS  Google Scholar 

  • CLSI (2012) Performance standards antimicrobial susceptibility testing; twenty-second informational supplement. Report, clinical and laboratory standard institution

  • da Silva LV, Araújo MT, Santos KRND, Nunes APF (2011) Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp strains. Mem Inst Oswaldo Cruz 106(1):44–50

    Article  Google Scholar 

  • Deresinski S (2007) Counterpoint: vancomycin and Staphylococcus aureus—an antibiotic enters obsolescence. Clin Infect Dis 44(12):1543–1548

    Article  CAS  Google Scholar 

  • Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M, the SENTRY Participants Group (2001) Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 32(Suppl12):S114–S132

    Article  CAS  Google Scholar 

  • Dong H, Wang N, Zhao L, Lu F (2012) Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med 2012:1–12

    Article  Google Scholar 

  • EUCAST (2012) Breakpoint tables for interpretations of MICs and zone diameters (version 6.1). Report, European Committee on antimicrobial susceptibility testing

  • Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR (2007) Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 35(2):240–245

    Article  CAS  Google Scholar 

  • Han Y, Lee JH (2005) Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol Pharm Bull 28(3):541–544

    Article  CAS  Google Scholar 

  • Howden BP, Grayson ML (2006) Dumb and dumber—the potential waste of a useful anti-staphylococcal agent: emergence of fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 42(3):394–400

    Article  CAS  Google Scholar 

  • Howden B, Davies J, Johnson P, Stinear T, Grayson M (2010) Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23(1):99–139

    Article  CAS  Google Scholar 

  • Jacqueline C, Navas D, Batard E, Miegeville AF, Le Mabecque V, Kergueris MF et al (2005) In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49(1):45–51

    Article  CAS  Google Scholar 

  • Kobayashi Y (2005) Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother 11(5):259–261

    Article  CAS  Google Scholar 

  • Kollef MH (2007) Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 45(Suppl3):S191–S195

    Article  CAS  Google Scholar 

  • Lemaire S, Bambeke FV, Pierard D, Appelbaum PC, Tulkens PM (2011) Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. Clin Infect Dis 52(S7):S493–S503

    Article  CAS  Google Scholar 

  • Lorian V (2005) Antibiotics in laboratory medicine, 5th edn. Lippincot Williams & Wilkins, Philadelphia

    Google Scholar 

  • Moellering RC Jr (2006) Vancomycin: a 50-year reassessment. Clin Infect Dis 42(suppl 1):S3–S4

    Article  Google Scholar 

  • Musumeci R, Speciale A, Costanzo R, Annino A, Ragusa S, Rapisarda A, Pappalardo MS, Lauk L (2003) Berberis aetnensis C. Presl. extracts: antimicrobial properties and interaction with ciprofloxacin. Int J Antimicrob Agents 22(1):48–53

    Article  CAS  Google Scholar 

  • Nagaev I, Bjorkman J, Andersson DI, Hughes D (2001) Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 40(2):433–439

    Article  CAS  Google Scholar 

  • O’Neill AJ, Larsen AR, Henriksen AS, Chopra I (2004) A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob Agents Chemother 48(9):3594–3597

    Article  Google Scholar 

  • O’Neill AJ, Larsen AR, Skov R, Henriksen AS, Chopra I (2007) Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol 45(5):1505–1510

    Article  Google Scholar 

  • Rand KH, Houck HJ (2004) Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48(8):2871–2875

    Article  CAS  Google Scholar 

  • Rochon-Edouard S, Pestel-Caron M, Lemeland JF, Caron F (2000) In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 44(11):3055–3060

    Article  CAS  Google Scholar 

  • Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009a) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49(3):325–327

    Article  Google Scholar 

  • Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP (2009b) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66(1):82–98

    Article  CAS  Google Scholar 

  • Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42(6):2398–2402

    Article  CAS  Google Scholar 

  • Singh V, Arora V, Jahangir-Alam M, Garey KW (2012) Inhibition of Biofilm Formation by Esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother 56(8):4360–4364

    Article  CAS  Google Scholar 

  • Soriano A, Martinez JA, Mensa J, Marco F, Almela M, Moreno-Martínez A, Sanchez F, Munoz I, Jimenez de Aanta MT, Soriano E (2000) Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 30(2):368–373

    Article  CAS  Google Scholar 

  • Steinkraus G, White R, Friedrich L (2007) Vancomycin MIC creep in non-vancomycin intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother 60(4):788–794

    Article  CAS  Google Scholar 

  • Turnidge J, Collignon P (1999) Resistance to fusidic acid. Int J Antimicrob Agents 12(Suppl 2):S35–S44

    Article  CAS  Google Scholar 

  • Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study.EPIC International advisory Committee. JAMA 274(8):639–644

    Article  CAS  Google Scholar 

  • Wu X, Li Q, Xin H, Yu A, Zhong M (2005) Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 61(8):567–572

    Article  CAS  Google Scholar 

  • Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY (2006) The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol 28(1):25–29

    Article  CAS  Google Scholar 

  • Yu HH, Kim KJ, Cha JD, Kim HK, Lee YE, Choi NY, You YO (2005) Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J Med Food 8(4):454–461

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Jie Xiong, Kun Li and Chao Wang from the General Hospital of Chengdu Military Command Region (Chengdu, China) for providing MRSA strains and offering technical help during the tests.

Author information

Author notes

  1. Rong-mei Liang

    Present address: Department of Clinical Pharmacy, General Hospital of Chengdu Military Command Region, 270 Rongdu Road, Chengdu, 610083, People’s Republic of China

Authors and Affiliations

  1. Department of Clinical Pharmacy, General Hospital of Chengdu Military Command Region, 270 Rongdu Road, Chengdu, 610083, People’s Republic of China

    Xiao-lan Yong, Yun-ping Jiang, Xiao-chun Huang, Zhao-hui Dong, Ting-ting Hu, Hui-qing Shi & Nan Li

  2. Department of Senior Carders Ward, General Hospital of Chengdu Military Command Region, Chengdu, 610083, People’s Republic of China

    Yu-qin Duan

  3. Department of Pharmacy, General Hospital of Chengdu Military Command Region, Chengdu, 610083, People’s Republic of China

    Yong-hong Tan, Yan Jiang & Shi-hua Wang

  4. Department of Clinical Laboratory Medicine, General Hospital of Chengdu Military Command Region, Chengdu, 61008, People’s Republic of China

    Ping Zeng & Zi-ying Zhou

Authors
  1. Rong-mei Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao-lan Yong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu-qin Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong-hong Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ping Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zi-ying Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yan Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shi-hua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yun-ping Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiao-chun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Zhao-hui Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ting-ting Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hui-qing Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Nan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rong-mei Liang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liang, Rm., Yong, Xl., Duan, Yq. et al. Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). World J Microbiol Biotechnol 30, 2861–2869 (2014). https://doi.org/10.1007/s11274-014-1712-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11274-014-1712-2

Keywords

Search

Navigation